Search Results
Sep 02, 2026, 08:30 ET Tom Lee's Fundstrat Capital Completes August 2026 Rebalance For All Granny Shots ETFs
(Allient Inc.); AMKR (Amkor Technology, Inc.); CFR (Cullen/Frost Bankers, Inc.); FORM (FormFactor, Inc.); MKSI (MKS Inc.); NVT (nVent Electric plc); PGEN (Precigen, Inc.); VICR (Vicor Corporation)Deletions: DPZ (Domino's Pizza, Inc.); ELF (e.l.f. Beauty, Inc.); NBIX (Neurocrine Biosciences, Inc.);
More news about: Fundstrat Capital
Aug 04, 2026, 16:01 ET Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today
More news about: Precigen, Inc.
Jul 21, 2026, 08:00 ET Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today
More news about: Precigen, Inc.
Jun 11, 2026, 08:00 ET Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and
More news about: Precigen, Inc.
May 30, 2026, 14:30 ET Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today
More news about: Precigen, Inc.
May 27, 2026, 07:00 ET Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
GERMANTOWN, Md., May 27, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today
More news about: Precigen, Inc.
May 26, 2026, 08:05 ET Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today
More news about: Precigen, Inc.
May 13, 2026, 16:05 ET Precigen Reports First Quarter 2026 Financial Results and Business Updates
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today
More news about: Precigen, Inc.
May 07, 2026, 16:05 ET Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today
More news about: Precigen, Inc.
Mar 30, 2026, 08:30 ET Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today
More news about: Precigen, Inc.
Mar 25, 2026, 16:05 ET Precigen Reports Full Year 2025 Financial Results and Business Updates
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today
More news about: Precigen, Inc.
Mar 11, 2026, 16:05 ET Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today
More news about: Precigen, Inc.
Jan 20, 2026, 08:05 ET New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today
More news about: Precigen, Inc.
Jan 12, 2026, 08:00 ET Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today
More news about: Precigen, Inc.
Jan 05, 2026, 16:05 ET Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
GERMANTOWN, Md., Jan. 5, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision medicines, today announced that Helen Sabzevari, PhD, President and Chief Executive Officer
More news about: Precigen, Inc.
Nov 13, 2025, 16:05 ET Precigen Reports Third Quarter 2025 Financial Results and Business Updates
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced third
More news about: Precigen, Inc.
Nov 06, 2025, 16:30 ET Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the
More news about: Precigen, Inc.
Oct 13, 2025, 07:00 ET Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced long-term
More news about: Precigen, Inc.